OUR BLOG
Insights
-
Mostapha Benhenda of Startcrowd on AI Drug Discovery Hype
For this episode of the Artificial Intelligence in Drug Discovery podcast, I spoke with Mostapha Benhenda of Startcrowd about a controversial article critiquing several research labs and how the field evolved since he wrote it.
-
Recent Advances in Treatment of Stage IV Metastatic Breast Cancer: Anti-HER2 mAbs, TKIs, and ADCs
We summarize the landmark studies over the past two decades that established the roles of anti-HER2 antibodies, antibody-drug conjugates, and tyrosine kinase inhibitors in Stage IV metastatic breast cancer.
-
Mauro Cozzi, Co-founder of Researchably, on AI for Better Biomedical Search
For this episode of the Artificial Intelligence in Drug Discovery podcast, I spoke with Mauro Cozzi, co-founder of Researchably. Learn how it got started, how it helps researchers find relevant literature faster, and the challenges they’re working to overcome to continue their growth.
-
Dekel Gelbman, CEO of FDNA, on “Next-Generation Phenotyping”
For the inaugural episode of Artificial Intelligence in Drug Discovery, I spoke with Dekel Gelbman, CEO of FDNA. Listen now to learn what inspired their technology, the problems it solves, how it can help in the drug discovery process, and where FDNA plans to take it.
-
A Novel Method to Evaluate Clinical Efficacy of Pre-Infusion CD19 CAR-T Products
In this article, we describe a novel single-cell 16-plexed method to evaluate potential therapeutic efficacy of pre-infusion CD19 CART-T products.
-
Polyclonal Vs Monoclonal Vs Recombinant Antibodies: What’s the Difference?
Almost all biomedical research scientists use antibodies at some point. Knowing how they were generated is critical in the selection of antibodies for your experiments. Read on to find out more.
-
Choosing the Right Immunoassays for Your Radiobiology Experiments
Here are various immunoassays commonly used in radiobiology experiments. Read on to find out which one is suitable for your study and its bench tips.
-
Advances in Treatment of Stage IV Metastatic Non-Small Cell Lung Cancer: The Role of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and Tyrosine Kinase Inhibitors
We summarize the landmark studies over the past two decades that established the roles of anti-EGFR antibodies and TK inhibitors in Stage IV metastatic NSCLC.
-
Overview of Innate Lymphoid Cells (ILCs): Subtypes, Characterization and Function
What are Innate Lymphoid Cells (ILCs)? Here we summarize the different subtypes, how to characterize them, their functions, and a list of published antibodies to study ILCs.